Faculty Profiles - MAEDA Yoshinobu

Regulatory T cells and IL-17-producing cells in graft-versus-host disease International journal

Takanori Teshima, Yoshinobu Maeda, Katsutoshi Ozaki

IMMUNOTHERAPY 3 ( 7 ) 833 - 852 2011.7

Language：English Publisher：FUTURE MEDICINE LTD

Graft-versus-host disease (GvHD), a major complication following allogeneic hematopoietic stem cell transplantation, is mediated by donor-derived T cells. On activation with alloantigens expressed on host antigen-presenting cells, naive CD4(+) T cells differentiate into T-helper cell subsets of effector T cells expressing distinct sets of transcriptional factors and cytokines. Classically, acute GvHD was suggested to be predominantly related to Th1 responses. However, we now face a completely different and complex scenario involving possible roles of newly identified Th17 cells as well as Tregs in GvHD. Accumulating data from experimental and clinical studies suggest that the fine balance between Th1, Th2, Th17 and Tregs after transplantation may be an important determinant of the severity, manifestation and tissue distribution of GvHD. Understanding the dynamic process of reciprocal differentiation of regulatory and T-helper cell subsets as well as their interactions will be important in establishing novel strategies for preventing and treating GvHD.

DOI： 10.2217/IMT.11.51

Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type International journal

Daisuke Ennishi, Yoshinobu Maeda, Nobuharu Fujii, Eisei Kondo, Katsuji Shinagawa, Kazuma Ikeda, Koichi Ichimura, Tadashi Yoshino, Mitsune Tanimoto

LEUKEMIA & LYMPHOMA 52 ( 7 ) 1255 - 1261 2011.7

Language：English Publisher：INFORMA HEALTHCARE

The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

DOI： 10.3109/10428194.2011.572322

Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation

Yoshihiko Soga, Yoshinobu Maeda, Fumihiko Ishimaru, Mitsune Tanimoto, Hiroshi Maeda, Fusanori Nishimura, Shogo Takashiba

SUPPORTIVE CARE IN CANCER 19 ( 7 ) 995 - 1000 2011.7

Language：English Publisher：SPRINGER

DOI： 10.1007/s00520-010-0923-9

中枢神経系悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

近藤英生, 前田嘉信, 青山一利, 吉田将平, 原嘉孝, 廻勇輔, 新谷大悟, 品川克至, 西森久和, 藤井敬子, 藤井伸治, 黒住和彦, 市川智継, 谷本光音

日本リンパ網内系学会会誌 51 98 - 98 2011.6

Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan

Katsuhiro Miura, Hirotaka Takasaki, Hideki Tsujimura, Masatoshi Kanno, Yoshinobu Maeda, Naoto Tomita, Kazue Takai, Yasufumi Masaki, Jun Takizawa, Hiraku Mori, Yasushi Terasaki, Takashi Yoshida, Jin Takeuchi, Shigeki Motomura

INTERNATIONAL JOURNAL OF HEMATOLOGY 93 ( 5 ) 684 - 686 2011.5

Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward

Yoshihiko Soga, Yuko Sugiura, Kanayo Takahashi, Hitomi Nishimoto, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

SUPPORTIVE CARE IN CANCER 19 ( 2 ) 303 - 307 2011.2

Language：English Publisher：SPRINGER

Oral mucositis is a common symptomatic complication associated with hematopoietic stem cell transplantation (HCT). We use simple strategies aimed to reduce oral mucositis by keeping the oral cavity clean and moist. Here, we report on the progress of oral care and the changes in the degree of oral mucositis. The purpose of this pilot study is to evaluate the effects of our strategies on the prevalence and the severity of oral mucositis.
Fifty-three consecutive patients from 2003 to 2006 administered with conventional allogeneic HCT were enrolled in this study. The degree of oral mucositis was evaluated daily in all patients. Our oral care program was divided into two periods: "examination and trial period (2003 and 2004)" and "intensive oral care period (2005 and 2006)." In the latter, an oral care regimen was carried out systematically by a multidisciplinary team.
Using our oral care strategies, the prevalence of ulcerative oral mucositis was decreased significantly. The rate was reduced from 76% (10 of 13) of patients with ulcerative oral mucositis in 2003 to only 20% (3 of 15) in 2006.
Our pilot study suggests that oral mucositis in HCT patients can be alleviated by simple strategies aimed at keeping the oral cavity clean and moist.

DOI： 10.1007/s00520-010-1002-y

Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward International journal

Yoshihiko Soga, Yuko Sugiura, Kanayo Takahashi, Hitomi Nishimoto, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

SUPPORTIVE CARE IN CANCER 19 ( 2 ) 303 - 307 2011.2

Language：English Publisher：SPRINGER

DOI： 10.1007/s00520-010-1002-y

医歯看連携による組織的な口腔内管理は造血細胞移植患者の口腔粘膜障害を減少させる

苅田典子, 曽我賢彦, 杉浦裕子, 高橋郁名代, 西本仁美, 前田嘉信, 谷本光音, 高柴正悟

日本造血細胞移植学会総会プログラム・抄録集 33rd 2011

Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?

Ogata Y, Aoe K, Hiraki A, Murakami K, Kishino D, Chikamori K, Maeda T, Ueoka H, Kiura K, Tanimoto M

Acta Med Okayama 65 ( 4 ) 259 - 263 2011

ドナーのTh17細胞とTh1細胞が慢性GVHD発症に関与する

西森久和, 前田嘉信, 杉山暖子, 小林孝一郎, 山筋好子, 門久幸代, 竹内賢吾, 谷本光音

日本造血細胞移植学会総会プログラム・抄録集 33rd 2011

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis International journal

Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, Shigeru Kusumoto, Masataka Okamoto, Masahiro Yokoyama, Yasushi Takamatsu, Kazutaka Sunami, Akira Miyata, Kayoko Murayama, Akira Sakai, Morio Matsumoto, Katsuji Shinagawa, Akinobu Takaki, Keitaro Matsuo, Tomohiro Kinoshita, Mitsune Tanimoto

BLOOD 116 ( 24 ) 5119 - 5125 2010.12

Language：English Publisher：AMER SOC HEMATOLOGY

The influence of hepatitis C virus (HCV) infection on prognosis and hepatic toxicity in patients with diffuse large B-cell lymphoma in the rituximab era is unclear. Thus, we analyzed 553 patients, 131 of whom were HCV-positive and 422 of whom were HCV-negative, with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)-like chemotherapy. Survival outcomes and hepatic toxicity were compared according to HCV infection. The median follow-up was 31 and 32 months for patients who were HCV-positive and HCV-negative, respectively. HCV infection was not a significant risk factor for prognosis (3-year progression-free survival, 69% vs 77%, P = .22; overall survival, 75% vs 84%, P = .07). Of 131 patients who were HCV-positive, 36 (27%) had severe hepatic toxicity (grade 3-4), compared with 13 of 422 (3%) patients who were HCV-negative. Multivariate analysis revealed that HCV infection was a significant risk factor for severe hepatic toxicity (hazard ratio: 14.72; 95% confidence interval, 6.37-34.03; P < .001). An exploratory analysis revealed that pretreatment transaminase was predictive of severe hepatic toxicity. HCV-RNA levels significantly increased during immunochemotherapy (P = .006). These results suggest that careful monitoring of hepatic function and viral load is indicated during immunochemotherapy for HCV-positive patients. (Blood. 2010;116(24):5119-5125)

DOI： 10.1182/blood-2010-06-289231

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

BLOOD 116 ( 24 ) 5119 - 5125 2010.12

Language：English Publisher：AMER SOC HEMATOLOGY

DOI： 10.1182/blood-2010-06-289231

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

Saiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, Naoyuki Uchida, Toru Sakura, Heiwa Kanamori, Kensuke Usuki, Takuya Yamashita, Yasushi Okoshi, Hirohiko Shibayama, Hirohisa Nakamae, Momoko Mawatari, Kazuo Hatanaka, Kazutaka Sunami, Manabu Shimoyama, Naohito Fujishima, Yoshinobu Maeda, Ikuo Miura, Yoichi Takaue, Takahiro Fukuda

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95 ( 11 ) 1857 - 1864 2010.11

Language：English Publisher：FERRATA STORTI FOUNDATION

Background
Patients with acute myeloid leukemia who are treated with conventional chemotherapy still have a substantial risk of relapse; the prognostic factors and optimal treatments after relapse have not been fully established. We, therefore, retrospectively analyzed data from patients with acute myeloid leukemia who had achieved first complete remission to assess their prognosis after first relapse.
Design and Methods
Clinical data were collected from 70 institutions across the country on adult patients who were diagnosed with acute myeloid leukemia and who had achieved a first complete remission after one or two courses of induction chemotherapy.
Results
Among the 1,535 patients who were treated with chemotherapy alone, 1,015 relapsed. Half of them subsequently achieved a second complete remission. The overall survival was 30% at 3 years after relapse. Multivariate analysis showed that achievement of second complete remission, salvage allogeneic hematopoietic cell transplantation, and a relapse-free interval of 1 year or longer were independent prognostic factors. The outcome after allogeneic transplantation in second complete remission was comparable to that after transplantation in first complete remission. Patients with acute myeloid leukemia and cytogenetic risk factors other than inv(16) or t(8;21) had a significantly worse outcome when they did not undergo salvage transplantation even when they achieved second complete remission.
Conclusions
We found that both the achievement of second complete remission and the application of salvage transplantation were crucial for improving the prognosis of patients with acute myeloid leukemia in first relapse. Our results indicate that the optimal treatment strategy after first relapse may differ according to the cytogenetic risk.

DOI： 10.3324/haematol.2010.027516

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse International journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95 ( 11 ) 1857 - 1864 2010.11

Language：English Publisher：FERRATA STORTI FOUNDATION

DOI： 10.3324/haematol.2010.027516